CFDE Data Portal | Search UBE2R2-AS1

	Label	Description
	UBE2R2-AS1 Gene (Entity type)	ENSG00000235481 - UBE2R2 antisense RNA 1
	GSE208634 1 V 2 DOXYCYCLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 12 V 0 NICOTINAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 10 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 5 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS

UBE2R2-AS1

ENSG00000235481 - UBE2R2 antisense RNA 1

GSE208634 1 V 2 DOXYCYCLINE HUMAN DN

A Gene Set from LINCS

GSE233679 12 V 0 NICOTINAMIDE HUMAN UP

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE100148 EZH2 inhibition 10 v 5 human dn

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 7 human up

A Gene Set from LINCS

GSE193993 SSTR2 knockout 5 v 3 human dn

A Gene Set from LINCS

GSE144843 GSE144844 SMARCA2 SMARCA4 knockdown 5 v 4 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.